Summary
Pulmonary toxicity was less frequent in pepleomycin treatment of squamous cell carcinoma than in bleomycin treatment. The tumor-regressing effect appeared at about day 10 of pepleomycin treatment, and at about day 21 of bleomycin treatment. The cumulative dose of pepleomycin to complete remission was smaller than that of bleomycin. Pepleomycin is effective against bleomycin-sensitive malignancies: squamous cell carcinoma and Hodgkin’s disease. It is more effective than bleomycin against lymph node metastases. Pepleomycin may have a broader antitumor spectrum: prostatic carcinoma responded.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hashimoto K, Shioda S, Amagasa T, Shimizu M, Sato O, Ito H, Fujibayashi T, Soda T (1979) Clinical experience with pepleomycin (NK631). Jpn J Antibiot 32:451–462
Hayashida K, Watanabe H, Ito M, Nakashima T, Toriya Y, Hiroto I, Jingu K, Hayabuchi N (1979) Clinical application of NK631 in the treatment of cancer of the tongue and floor of the mouth. Jpn J Antibiot 32:509–515
Ichikawa T (1976) Studies of bleomycin; discovery of its clinical effect, combination treatment with bleomycin and radiotherapy, side effects, and long-term survival. GANN Monogr Cancer 19:99–115
Iida T, Matsumoto K, Komiyama H, Okano H, Inaba O, Ogawa F, Takeda G, Takasu J (1978) Clinical experience with NK-631 in the case of oral cancer. Jpn J Oral Surg 24:983–992
Ikeda S, Miyasato H, Nakayama H, Kobayashi Y, Tajima K (1979) Clinical trial of pepleomycin for the malignant skin tumors. Jpn Cancer Clin 25:677–687
Inuyama Y, Murakami Y, Kohno N, Mashino S, Asaoka K, Nakajima Y, Ozu R, Horiuchi M (1978) Clinical effect of NK-631 (pepleomycin) for head and neck cancer. Practica Otologica (Kyoto) 71:1517–1527
Majima H, Oguro M, Takagi T (1979) Preclinical trial of NK631 of malignant lymphoma. Cancer Chemother 6:401–404
Matsuda A, Yoshioka O, Yamashita T, Ebihara K, Umezawa H, Takeuchi T, Miura T, Katayama K, Yokoyama M, Nagai S (1978) Fundamental and clinical studies on new bleomycin analogs. Recent Results Cancer 63:191–210
Miura T, Katayama K, Wada T (1979) Phase I and phase II studies of a new bleomycin (pepleomycin). Jpn J Antibiot 32:265–277
Nobe O, Kubo H, Yoshii K, Tashiro M (1979) Clinical experience with NK631 in malignant tumors of skin. Jpn J Antibiot 32:463–469
Sekiya T, Kawabe Y, Ito A, Kaneda T, Suzuki T, Shiraishi T (1979) A joint study of NK631 treatment of head and neck cancers. Cancer Chemother 6:777–784
Takata K, Honda T (1979) Primary effect of NK631 against head-and-neck cancers. Jpn J Antibiot 32:106–114
Tanaka W (1977) Development of new bleomycins with potential clinical utility. Jpn J Antibiot [suppl] 30:41–48
Ueno T, Shimizu M, Michi K, Ishibashi K, Kohama G (1973) Klinische Erfahrungen iiber die Behandlung mit Bleomycin von 551 Fallen der Mundhohlenkarzinome in Japan. Bull Tokyo Med Dent Univ 62:117–126
Umezawa H (1976) Bleomycin; discovery, chemistry, and action. GANN Monogr Cancer Res 19:3–36
Yokoyama M, Sato K, Wakui A, Saito T (1979) Phase I and phase II study of new bleomycin analogs - NK5033 and NK631. Cancer Chemother 6:749–758
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Oka, S. (1980). A Review of Clinical Studies of Pepleomycin. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 74. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81488-4_21
Download citation
DOI: https://doi.org/10.1007/978-3-642-81488-4_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81490-7
Online ISBN: 978-3-642-81488-4
eBook Packages: Springer Book Archive